{
  "question_stem": {
    "en": "A 58-year-old man comes to the office due to progressive fatigue, dyspnea on exertion, and orthopnea. Medical history is significant for hypertension, hyperlipidemia, and a myocardial infarction 2 years ago. The patient says he has not taken his medications in several months because he was \"feeling well.\" Blood pressure is 160/95 mm Hg and pulse is 94/min and regular. Physical examination shows bilateral lung crackles and lower extremity edema. The point of maximal impulse is displaced toward the axilla, and an S3 is heard. Serum creatinine is 0.9 mg/dL and serum potassium is 4.2 mEq/L. After this patient's condition has stabilized, long-term use of which of the following medications will most likely reduce mortality?",
    "zh": "一名58岁男性因进行性疲劳、劳力性呼吸困难和端坐呼吸就诊。病史提示高血压、高脂血症和2年前发生的心肌梗死。患者说他几个月没有服药，因为他“感觉良好”。血压为160/95 mmHg，脉搏94次/分，规律。体格检查显示双肺有啰音和下肢水肿。心尖搏动点移位至腋下，可闻及S3奔马律。血清肌酐为0.9 mg/dL，血清钾为4.2 mEq/L。在该患者病情稳定后，长期使用以下哪种药物最有可能降低死亡率？"
  },
  "question": {
    "en": "After this patient's condition has stabilized, long-term use of which of the following medications will most likely reduce mortality?",
    "zh": "在该患者病情稳定后，长期使用以下哪种药物最有可能降低死亡率？"
  },
  "options": {
    "A": {
      "en": "Amlodipine",
      "zh": "氨氯地平"
    },
    "B": {
      "en": "Digoxin",
      "zh": "地高辛"
    },
    "C": {
      "en": "Diltiazem",
      "zh": "地尔硫卓"
    },
    "D": {
      "en": "Furosemide",
      "zh": "呋塞米"
    },
    "E": {
      "en": "Hydrochlorothiazide",
      "zh": "氢氯噻嗪"
    },
    "F": {
      "en": "Lisinopril",
      "zh": "赖诺普利"
    },
    "G": {
      "en": "Triamterene",
      "zh": "氨苯蝶啶"
    }
  },
  "correct_answer": "F",
  "explanation": {
    "en": "This patient with a previous myocardial infarction has most likely developed chronic HEART FAILURE WITH REDUCED EJECTION FRACTION (HFrEF). Appropriate pharmacologic management is important in such patients because it has been shown to reduce mortality. Much of this MORTALITY BENEFIT is likely related to a REDUCTION in deleterious cardiac remodeling. \n\nNeurohormonal pathways involving norepinephrine, angiotensin II, and aldosterone all have a demonstrated role in cardiac remodeling. In particular, elevated angiotensin II and aldosterone levels increase pathologic cardiomyocyte hypertrophy and stimulate collagen deposition by fibroblasts (cardiac fibrosis). Accordingly, ACE INHIBITORS (eg, lisinopril), ANGIOTENSIN-RECEPTOR BLOCKERS (eg, losartan), and MINERALOCORTICOID RECEPTOR ANTAGONISTS (eg, spironolactone, eplerenone) reduce mortality in patients with HFrEF via a reduction in angiotensin II-mediated (and downstream aldosterone-mediated) cardiac remodeling.\n\nBETA BLOCKERS (eg, metoprolol, carvedilol) also reduce mortality in patients with chronic HFrEF, likely through similar inhibition of neurohormonal mechanisms. Potentiation of the natriuretic peptide neurohormonal pathway with ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR therapy (eg, sacubitril-valsartan) has also demonstrated mortality benefit in these patients.\n\n(Choice A) Blood pressure control is important for patients with heart failure because it slows the progression of coronary artery disease and may reduce cardiac remodeling that is triggered by increased left ventricular pressure load. However, aside from the benefit of blood pressure reduction, dihydropyridine calcium channel blockers (eg, amlodipine) provide no additional mortality benefit in patients with HFrEF.\n\n(Choice B) Digoxin is used as an adjunctive therapy in patients with HFrEF. It improves symptoms, thereby reducing the rate of hospitalization, but does not improve mortality.\n\n(Choice C) Nondihydropyridine calcium channel blockers (eg, verapamil, diltiazem) can depress cardiac contractility and are usually contraindicated in patients with HFrEF.\n\n(Choices D and E) Loop (eg, furosemide) and thiazide (eg, metolazone) diuretics reduce cardiac preload and are useful for symptomatic management of patients with HFrEF; however, these drugs do not provide a clear mortality benefit.\n\n(Choice G) Although potassium-sparing diuretics that function via blockade of mineralocorticoid receptors have shown mortality benefit for HFrEF, those that act via blockade of the epithelial sodium channel (ENaC) (eg, triamterene, amiloride) have minimal neurohormonal effects and no demonstrated benefit.\n\nEducational objective:\nNeurohormones (eg, norepinephrine, angiotensin II, and aldosterone) play a large role in the deleterious cardiac remodeling that occurs in heart failure with reduced ejection fraction. ACE inhibitors, angiotensin-receptor blockers, mineralocorticoid receptor antagonists, beta blockers, and angiotensin receptor-neprilysin inhibitors reduce mortality in these patients by reducing neurohormonal-mediated cardiac remodeling.",
    "zh": "该既往有心肌梗死病史的患者很可能发展为慢性射血分数降低的心力衰竭 (HFrEF)。在这种患者中，适当的药物治疗非常重要，因为它已被证明可以降低死亡率。这种死亡率获益的大部分可能与有害的心脏重塑的减少有关。\n\n涉及去甲肾上腺素、血管紧张素II和醛固酮的神经内分泌途径均已证实参与心脏重塑。特别是，血管紧张素II和醛固酮水平升高会增加病理性心肌细胞肥大，并刺激成纤维细胞（心脏纤维化）的胶原沉积。因此，ACE抑制剂（例如，赖诺普利）、血管紧张素受体阻滞剂（例如，氯沙坦）和盐皮质激素受体拮抗剂（例如，螺内酯、依普利酮）通过减少血管紧张素II介导的（以及下游醛固酮介导的）心脏重塑，降低HFrEF患者的死亡率。\n\nβ受体阻滞剂（例如，美托洛尔、卡维地洛）也降低了慢性HFrEF患者的死亡率，这可能通过类似地抑制神经内分泌机制。使用血管紧张素受体-脑啡肽酶抑制剂治疗（例如，沙库巴曲-缬沙坦）增强利钠肽神经内分泌通路也已证明了这些患者的死亡率获益。\n\n（选项 A）血压控制对心力衰竭患者很重要，因为它可以延缓冠状动脉疾病的进展，并可能减少由左心室压力负荷增加引起的心脏重塑。然而，除了降血压的益处外，二氢吡啶类钙通道阻滞剂（例如，氨氯地平）对HFrEF患者没有额外的死亡率获益。\n\n（选项 B）地高辛用于HFrEF患者的辅助治疗。它可改善症状，从而降低住院率，但不能改善死亡率。\n\n（选项 C）非二氢吡啶类钙通道阻滞剂（例如，维拉帕米、地尔硫卓）会抑制心肌收缩力，通常不适用于HFrEF患者。\n\n（选项 D 和 E）袢利尿剂（例如，呋塞米）和噻嗪类利尿剂（例如，美托拉宗）可降低心脏前负荷，并用于HFrEF患者的对症治疗；然而，这些药物不能提供明确的死亡率获益。\n\n（选项 G）虽然通过阻断盐皮质激素受体发挥作用的保钾利尿剂已显示出对HFrEF的死亡率获益，但通过阻断上皮钠通道（ENaC）（例如，氨苯蝶啶、阿米洛利）发挥作用的药物，其神经内分泌效应很小，且未显示出益处。\n\n教育目的：\n神经激素（例如，去甲肾上腺素、血管紧张素II和醛固酮）在射血分数降低的心力衰竭中发生的有害心脏重塑中起重要作用。ACE抑制剂、血管紧张素受体阻滞剂、盐皮质激素受体拮抗剂、β受体阻滞剂和血管紧张素受体-脑啡肽酶抑制剂通过减少神经激素介导的心脏重塑，从而降低这些患者的死亡率。"
  },
  "summary": {
    "en": "This question tests knowledge of the appropriate pharmacologic management of chronic heart failure with reduced ejection fraction (HFrEF) and which medications have been shown to reduce mortality in these patients.\n\nTo solve this question, recognize the signs and symptoms of HFrEF in the patient presentation. Then, recall the medications that have demonstrated mortality benefit in HFrEF, including ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, beta blockers, and angiotensin receptor-neprilysin inhibitors.",
    "zh": "此问题测试对慢性射血分数降低的心力衰竭（HFrEF）的适当药物治疗以及哪些药物已被证明可降低这些患者的死亡率的认识。\n\n要解决此问题，请识别患者表现中HFrEF的体征和症状。然后，回忆在HFrEF中已显示出死亡率获益的药物，包括ACE抑制剂、血管紧张素受体阻滞剂、盐皮质激素受体拮抗剂、β受体阻滞剂和血管紧张素受体-脑啡肽酶抑制剂。"
  },
  "tags": "Heart failure; Reduced ejection fraction; ACE inhibitors; Angiotensin receptor blockers; Mineralocorticoid receptor antagonists; Beta blockers; Angiotensin receptor-neprilysin inhibitors; Mortality benefit; Cardiac remodeling; Cardiology",
  "category": "CVS",
  "question_id": "1565",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\1565",
  "extracted_at": "2025-11-05T12:00:01.057296",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:50:45.390117",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}